Blog

Psychedelic Analogues Solve The Problems Of Limiting Psychedelic Treatment Model

Sep 15 • 17 min read

Traditional psychedelics have shown great potential for treating issues like depression, anxiety, PTSD, and addiction. Psilocybin and MDMA will likely be available for patients in the next couple of years with other psychedelic compounds like LSD and DMT following suit. Even if these compounds can significantly help those who have access to them, there are…

Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter

Sep 15 • 3 min read

Wellbeing Digital Sciences Inc., (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that it has filed its financial results for the quarter ended July 31, 2022, the highlights of which are…

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

Sep 15 • 2 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party investor…

MINDCURE Announces Financial Results for Fiscal 2022

Sep 15 • 1 min read

Mind Cure Health Inc. (CSE: MCUR | OTCQX: MCURF | FRA: 6MH) today announced its financial results for the three and twelve months ended May 31, 2022. All amounts are stated in Canadian dollars unless otherwise indicated. The special committee of the Company’s board of directors is continuing to explore, review and evaluate a broad range of…

CaaMTech Publishes Fundamental Research on Aeruginascin Derivatives

Sep 14 • 3 min read

In collaboration with the Manke Lab at UMass Dartmouth and the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program, CaaMTech scientists continue to pioneer new fields of “magic mushroom” research with their latest published academic work, “Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines.” Published in the American Chemical…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543